ARTICLE | Company News
Merck bets on HIF2As with Peloton takeout ahead of planned listing
May 21, 2019 3:32 PM UTC
Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck & Co.
Shareholders of Peloton Therapeutics Inc. (Dallas, Texas) will receive $1.05 billion up front and are eligible for another $1.15 billion in undisclosed milestones...
BCIQ Target Profiles
Endothelial PAS domain protein 1 (HIF2A) (HIF-2alpha) (EPAS1)